Article
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2009
Quintás-Cardama Alfonso, Kantarjian Hagop M, Manshouri Taghi, Thomas Deborah, Cortes Jorge, Ravandi Farhad, Garcia-Manero Guillermo, Ferrajoli Alessandra, Bueso-Ramos Carlos, Verstovsek Srdan
Abstract excerpt
PURPOSE: To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF). PATIENTS AND METHODS: Forty patients with MF were treated. Therapy consisted of lenalidomide 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) on days 1 through 21 of a 28-day cycle for six cycles, in combination with prednisone 30 mg/d orally during cycle 1, 15 mg/d...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.